Table 1. Primary and secondary endpoints of the Cardiac Health in Breast Cancer study.
| Endpoints | Description |
| Primary endpoint | |
| Occurrence of symptomatic/asymptomatic CTRCD | Assessment of cardiac structure and function using transthoracic echocardiography, CMR sequences, CPET and myocardial biomarkers (troponin T and N-terminal pro B-type natriuretic peptide) |
| Secondary endpoints | |
| Signs of cardiac inflammation | Detecting changes from baseline (t1) to follow-up (t2) and final examination (t3) by CMR imaging |
| Mitochondrial dysfunction | Mitochondrial and molecular markers (galectin-3, klotho, kynurenine, cell-free mitochondrial DNA and nuclear DNA, musclin, nuclear respiratory factor 2, peroxisome proliferator-activated receptor-γ coactivator-1α, rhodanase) |
| Health-related quality of life | EuroQol-five dimension questionnaire |
| Fatigue | European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-FA12 questionnaire |
| Depression | Patient Health Questionnaire-9 |
| Anxiety | Generalised Anxiety Disorder-7 questionnaire |
| Average heart rate | Tracked by the fitness watch |
| Heart rate variability | Tracked by the fitness watch |
| Step count and daily physical activity | Tracked by the fitness watch |
| Blood pressure | Assessment at baseline (t1), follow-up (t2) and final examination (t3) |
| Exercise capacity | CPET with an assessment of maximum oxygen uptake and maximum power |
| Strength capacity | Grip strength |
| Anthropometry | Body weight, body mass index, fat mass, free fat mass, waist-to-height-ratio |
CMRcardiac magnetic resonanceCPETcardiopulmonary exercise testingCTRCDcancer-therapy-related cardiac dysfunction